Pitrakinra

Pitrakinra is a recombinant protein that is designed to be a selective antagonist of the interleukin-4 receptor. It is used in the treatment of asthma and allergic diseases. The drug was developed by Aerovance, a biopharmaceutical company based in Berkeley, California.

Etymology

The name "Pitrakinra" is derived from the Greek words "pitra", meaning "against", and "kinra", meaning "movement". This reflects the drug's function as an antagonist, working against the movement of certain proteins in the body.

Mechanism of Action

Pitrakinra works by binding to the interleukin-4 receptor, preventing the binding of interleukin-4 and interleukin-13, two cytokines that are involved in the inflammatory response in asthma and allergic diseases. By blocking these cytokines, Pitrakinra reduces inflammation and improves symptoms.

Clinical Trials

Pitrakinra has been tested in several clinical trials. In a Phase II trial, the drug was found to significantly reduce asthma symptoms and improve lung function in patients with moderate to severe asthma. In another trial, Pitrakinra was found to be effective in reducing symptoms in patients with atopic dermatitis, a type of allergic skin disease.

Side Effects

Common side effects of Pitrakinra include injection site reactions, upper respiratory tract infections, and headache. Serious side effects can include severe allergic reactions.

See Also

• Interleukin-4 receptor
• Aerovance
• Recombinant protein
• Asthma
• Allergic diseases

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia